Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 7 points (0.0%) at 14,818 as of Tuesday, Sept. 3, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,623 issues advancing vs. 1,312 declining with 88 unchanged. The Drugs industry currently sits up 1.0% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Novartis ( NVS), up 2.2%, and GlaxoSmithKline ( GSK), up 1.6%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $13.55 (5.6%) to $255.86 on average volume. Thus far, 449,130 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 765,000 shares. The stock has ranged in price between $245.98-$257.80 after having opened the day at $245.99 as compared to the previous trading day's close of $242.31. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $23.4 billion and is part of the health care sector. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.